Principia Health Sciences / est. 2020 / Cary, NC
The connective fabric of collaborative research.
Twelve products, one platform. Principia builds CuRE networks that unify disease associations, clinics, patients, and industry on a single governed record. Data arrives as FHIR, lands on an OMOP core, and leaves submission-grade, so research moves at the speed of evidence rather than paperwork.
One platform. Twelve products.
One governed record.
At the heart of CuRE is one governed OMOP record. The Core — Conduit, Conduct, and Control — builds and governs it. The nine products each draw on that shared record and write value back, so the platform compounds instead of fragmenting.
9 products
Five reasons CuRE is different.
Not another EDC with a data lake bolted on. CuRE is built RWD-first, AI-native, and tightly integrated — at a price that does not assume an enterprise budget.
one thesis
RWD-native — data first, study second.
Patient and clinical data flow continuously into a governed common data model; studies layer on top of data that already exists. Multi-study, not one-protocol-at-a-time.
AI-native, with guardrails.
Intelligence is embedded across the platform — AI-assisted capture and validation, NLP/OCR, FHIR→OMOP mapping, decision support. Every suggestion is attributable and human-in-the-loop: confidence, sources, and correction paths, not generative hype.
Tight integration — one governed record.
One platform, one governed record across all twelve products. No flat-file islands or nightly reconciliation: every event lands on the same shared substrate, so products compose instead of bolting together.
No enterprise tax.
Exceedingly competitive pricing, friendly to non-profit and academic teams. Enterprise-grade compliance without the enterprise cost or per-seat surprises.
Fast startup.
Production-ready in weeks, not months. Rapid study build, and amendments are config diffs — not multi-week vendor projects.
Enterprise compliance, without the enterprise tax.
See how the platform fits togetherReal-world evidence happens in patient journeys.
Dense, not cramped.
Clinical research is information-rich. The interface earns space with alignment, tabular data, and hierarchy instead of padding everything into sameness.
Semantic color does real work.
Teal means automated, amber means attention, sky means information, and magenta marks AI-assisted work. Color carries state.
Context persists.
Study, site, patient, cohort, and time cursor should follow the user across surfaces, pages, and refreshes.
Provenance is visible.
Every important value should show whether it was entered, ingested, suggested, reviewed, locked, or overridden.
AI stays attributable.
AI features should expose confidence, source material, and correction paths instead of hiding authorship behind a magic button.
One patient record, stitched from every source.
EHRs, labs, registries, claims, patient apps, and cytogenetics map through open standards into one governed record — FHIR on the way in, OMOP as the analytical backbone, submission-grade SDTM/CDASH on the way out.
schematic
Section 04 / Try the tech
Karyotypes, parsed in the browser.
CuRE Cyto turns ISCN strings into structured data. Paste a karyotype or choose an example to see chromosome count, sex, abnormality type, breakpoints, and cell counts resolve on the page.
See the full cytogenetics workflowEnter an ISCN string above or click an example to see it parsed.
This is a lightweight demo — for full ISCN 2016/2020 parsing, visit cyto.principia.health
Engagement / NMDP
Modernizing a registry without disrupting operations.
NMDP maintains one of the world's most important transplant datasets. Our approach maps donor outcomes data to OMOP in place and adds continuous quality scoring — designed so no operational system has to go offline, and the OHDSI toolkit opens up on top.
Read the case studyWhy legacy EDC is holding back outcomes research.
Electronic data capture was built for trials, not for the longitudinal reality of outcomes research.
Read moreThe real-world evidence generation gap.
Everyone agrees RWE is the future. Almost nobody has the infrastructure to generate it systematically.
Read moreThe economics of real-world evidence.
The infrastructure-reuse multiplier is the only answer that scales when labor dominates RWE generation.
Read moreTalk to Principia
If you have a hard RWE question, we should talk.
We work with non-profits, health systems, and life-sciences organizations on programs ranging from a cytogenetics refresh to a full CuRE network.
No newsletters. A human reply within two business days.